Project cooperationUpdated on 9 April 2026
ASP210
About
ASP210 is a therapeutic oligonucleotide leveraging the ESiNAR-X platform to target BCR-ABL1 mRNA in patients with chronic myeloid leukemia who are resistant or refractory to TKI therapy.
Status: Finished pre-clinical validation
We are seeking investments and partnerships to support the execution of clinical trials.
Similar opportunities
Partnership
HIST — HistSHOCK & HistSHOCK CDx
James Webb
Chief Commercial Officer at EpiDisease SL
Valencia, Spain
Expertise
Digital Health Platform for Clinical Research
Linus Kao
CEO at Skyvor Medical AG
Basel, Switzerland
Partnership
Do Youn Chun
Chief Technical Officer at AT-31 BIO Inc.
Daegu, South Korea